 InPharm | Regorafenib Anticipated to Show Survival Advantage in Colorectal Cancer Family Practice News Digital Network Other noteworthy studies include a reanalysis of the phase III RADIANT-2 trial suggesting that everolimus (Afinitor) may be of greater benefit in neuroendocrine tumors than previously shown, and research that could improve the early detection of ... Experimental Drug Might Help Some a Bit With Colon Cancer |
